Q-omics provides the consensus-scored LETMD1 profile across patient tissues and cancer cell-line models. LETMD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LETMD1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LETMD1 RNA expression shows 20,227 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where LETMD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LETMD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LETMD1 survival associations across molecular data types. LETMD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LETMD1 RNA expression–survival associations across cancer types. High LETMD1 expression shows unfavorable associations in LIHC, COAD and ACC, but favorable associations in UVM, LGG and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for LETMD1 RNA expression.
This table summarizes LETMD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LETMD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LETMD1 shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, COAD, KICH and CHOL. The KIRC box plot shows higher LETMD1 RNA expression in tumor versus normal tissue (log2 FC = +0.312, t-test p < 0.001).
This table shows molecular features associated with LETMD1 in patient tissues and cancer cell lines. In patient samples, LETMD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LETMD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
